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Purpose: To identify proteins differentially expressed between the tear film of keratoconus (KC) patients and control
subjects using two dimensional electrophoresis (2-DE) and mass spectrometry-based techniques.
Methods: Twenty two patients (44 eyes) diagnosed with bilateral KC and 22 control subjects (44 eyes) were studied in
a prospective case-control study. Keratoconus screening programs and Orbscan II topographies were performed on all
participants. Tear samples were collected by the Schirmer I method using filter paper. Proteins were extracted from the
Schirmer strips and separated by 2-DE. Comparison of protein patterns was performed using PDQuest Software and
protein differences were identified by mass spectrometry. Finally, results were validated by western-blot.
Results: Four spots were identified to be differentially expressed between KC patients and control subjects. Three of them
were more expressed in healthy subjects and they were identified as zinc-α2-glycoprotein (ZAG), lactoferrin, and IGKC
(immunoglobulin kappa chain). The other spot was more expressed in KC patients and it was identified as ZAG.
Differences in ZAG seem controversial in two different spots because different posttranslational modifications, however,
analysis of both spots revealed that globally, ZAG is overexpressed in healthy subjects. Founded differences in ZAG,
lactoferrin, and IGKC expression were subsequently validated by western blot.
Conclusions: IGKC protein, ZAG, and lactoferrin are under-expressed in the tears of patients diagnosed with bilateral
KC compared with healthy subjects. These differences could contribute to the knowledge of the pathophysiology of this
disease.
Keratoconus (KC) is a primary corneal ectasia, generally
bilateral and progressive, with a conical shape as a result of
the thinning of the stroma. This thinning induces irregular
astigmatism,  myopia,  and  protusion,  leading  to  mild  to
marked impairment in the quality of vision [1]. KC has its
onset at puberty, and it progresses until the third or fourth
decade of life. The calculated incidence of KC is between
1/500 and 1/2,000 in the general population [1,2]. KC affects
young persons in a very productive period of their lives. Yet
the cause of this disorder, considered to be the most common
indication for penetrating keratoplasty in developed countries
[3], remains unknown.
KC may be isolated or may be associated with various
clinical  conditions,  or  even  form  part  of  a  syndrome.  Its
etiology remains poorly understood, but it has been reported
to arise as a consequence of biochemical alterations to corneal
collagenase, which breaks down collagen leading to stromal
thinning [4]. Other authors have suggested that it may arise as
a consequence of keratocyte loss [5], which is on average
about 19% lower in contact lens users [6]. In some atopic
diseases, KC may be due to apoptosis of corneal cells, possibly
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mediated by interleukin-1 [7]. Rahí et al. [8], found atopic
diseases in 35% of patients with KC, in contrast to 12% of
control  subjects.  KC  is  frequently  associated  with  ocular
itchiness and rubbing, provoking chronic epithelial lesions
[7]. The cornea is part of an integrated system - the ocular
surface - which contains specific and non-specific immune
molecules. Tissue degradation in thinning disorders, such as
KC, involves the expression of inflammatory mediators, such
as proinflammatory cytokines, cell adhesion molecules, and
matrix metalloproteinases [9-12]. Moreover, previous studies
from  our  group  have  demonstrated  that  the  levels  of
proinflammatory  cytokines  (interleukin-6  [IL-6]  and  the
tumor  necrosis  factor  alpha  [TNF-α])  and  matrix
metalloproteinase-9 (MMP-9) are significantly increased in
the tears of patients with KC [13]. Despite these advances,
there  are  currently  no  diagnostic  markers  of  KC  and  the
pathophysiology of this disease is largely unknown.
Proteomics is a discipline that study complex mixtures of
proteins. Two-dimensional electrophoresis (2-DE) and mass
spectrometry are very useful techniques to find out protein
differences  between  different  types  of  samples.  Tear
proteomics has been used to find out potential cancer markers
[14], to study responses in patients with fungal keratitis [15]
and for identification of tear proteases [16].
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2055Table 1 shows clinical characteristics of patients with
keratoconus  and  control  subjects.  No  age-related  or  sex-
related  statistical  differences  were  detected  between  KC
patients and control subjects. A family history of KC was
reported for 3 patients (13.6%) and 1 control (4.5%). Ten KC
patients (45.5%) and five controls (22.7%) were diagnosed as
having atopic disease (most commonly to pollen or acaroids).
Twelve KC patients (54.5%) admitted frequent and vigorous
eye rubbing and 3 control eye rubbing (13.6%).
In  this  study  we  used  proteomic  tools,  such  as  two
dimensional electrophoresis (2-DE) and mass spectrometry,
to find out protein differences in tear samples that allow the
differentiation  between  eyes  of  KC  patients  and  normal
controls.
METHODS
Subjects  and  clinical  examination:  We  have  designed  a
prospective, case-controlled study in which 22 bilateral KC
patients (44 eyes) and 22 normal control subjects (44 eyes)
were recruited from the Contact lens Unit, Instituto Galego de
Oftalmoloxía,  Complexo  Hospitalario  Universitario  de
Santiago de Compostela, Spain. KC patients (50.0% male;
mean age, 31.3±7.8 years) and control subjects (54.5% male;
mean age, 30.8±7.6 years) had not worn contact lenses for a
week prior the study. All patients were expressly cited for the
purposes of this study, and all examinations were performed
by the same researcher between September 2007 and April
2008. Data collected included gender, age, patient’s ocular
history (eye rubbing), medical history (atopy), and family
history of KC. This research was performed in accordance
with  the  Declaration  of  Helsinki  of  the  World  Medical
Association (2000). Protocol was approved by the Hospital's
Research Ethics Committee, and informed consent was given
by all patients and control subjects.
The biomicroscopy exam was performed to detect signs
of KC and the corneal topography study was performed to
quantify topographic parameters. The modified Rabinowitz-
McDonnell test was used to confirm the diagnosis of KC, and
the severity of KC was classified according to the steepest
simulated keratometry reading on the keratometric map (K2
<45 D, mild; K2 between 45 and 52 D, moderate; K2 >52 D,
severe KC) [17].
Inclusion criteria were; 1) Bilateral KC patients, severe
in both eyes or severe and moderate, with biomicroscopic
signs in both eyes. 2) Subjects in the control group with normal
corneal topography maps.
Exclusion  criteria  included;  1)  Previous  surgical
intervention in the anterior segment, or childhood corneal
trauma  or  disease.  2)  Existence  of  active  or  systemic
inflammation, or ocular disease, or current treatment with
systemic or local anti-inflammatory drugs.
Instrumental: Basic examination instruments were a Topcon
biomicroscope  and  Topcon  refraction  column  (Topcon,
Essebaan, Netherlands). As specific examination instruments
we used a Keratron Scout (Opticon 2000; SpA, Rome, Italy)
and an Orbscan II corneal topographer (Orbtek, Salt Lake
City, UT).
Two-dimensional  electrophoresis  was  performed  in
IPGphor (Bio-Rad, Hercules, CA) for the first dimension and
ETTAN-DALTSIX  for  second  dimension  (GE,  Uppsala,
Sweden). Western blot was performed using Miniprotean 3
system and Trans blot SD semi-dry transfer cell (Bio-Rad).
Gels  and  blots  were  digitized  in  FX-Proplus  (Bio-Rad).
Finally, MALDI-TOF mass spectrometer (MS) analyses were
performed using a 4700 Proteomics Analyzer MALDI TOF/
TOF MS (Applied Biosystems, Carlsbad, CA).
Tear  analysis:  Tear  samples  were  obtained  by  placing  a
Schirmer strip over the lower lip, approximately 3 mm from
the lateral canthus, without previous instillation of drugs or
vital dyes. The subject was instructed to close the eyes for the
5 min test duration, the wet length was not recorded but was
observed to be within normal ranges in all cases (>10 mm).
We collected four Schirmer strip for subject; samples were
frozen  and  stored  at  −20  °C  immediately.  Proteins  were
extracted from the Schirmer strips by incubating with 200 μl
of 100 mM ammonium bicarbonate at room temperature for
1 h. Then 600 μl cold acetone were added and incubated for
2 h at −20 °C. Precipitation of proteins was performed by
centrifugation  at  18,000×  g.  Precipitated  proteins  were
resuspended in solubilization buffer (9 M urea, 2% CHAPS).
Proteins were quantified by modified Bradford assay using
BSA as protein standard.
Two-dimensional electrophoresis: Two replicate gels were
performed for 12 patients (24 eyes) and 12 control subjects
TABLE 1. CLINICAL CHARACTERISTICS OF PATIENTS WITH KERATOCONUS AND CONTROL SUBJECTS.
Variables Keratoconus (n=22) Control (n=22) p
Age (years) 31.3±7.8 30.8±7.6 0.876
Males, n (%) 11 (50.0) 12 (54.5) 0.763
Atopic disease, n (%) 10 (45.5) 5 (22.7) 0.052
Eye rubbing, n (%) 12 (54.5) 3 (13.6) 0.005
K2, diopters 54.8±7.1 43.7±1.6 <0.0001
Thinnest P (μm) 386.2±71.6 542±23.9 <0.0001
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2056(24 eyes). Protein (20 μg) was applied on 17 cm 3–10NL IPG
strips and first dimension was performed until 45 kV h was
achieved.  Second  dimension  of  gel  electrophoresis  was
performed  on  12.5%  polyacrilamide  gels  on  ETTAN-
DALTSIX (GE) at 5 W per gel for 15 min, and then at 17 W
per gel until the dye front reached the bottom of the gel.
Analytical gels were stained with Flamingo Fluorescent Stain
and visualized on Molecular Imager FX Pro-plus (Bio-Rad).
Preparative  gels  were  stained  in  0.1%  Coomassie  Blue
Brilliant R-250.
Gels were digitalized using a Bio-Rad Molecular Imager
FX Pro-plus. Protein patterns were analyzed using PDQuest
7.0 from Bio-Rad. Gel spots of interest were manually excised
from preparative gels and digested according to Shevchenko
et al. [18].
MALDI-TOF  MS  analyses  were  performed.  The
obtained  peptide  mass  fingerprints  were  used  for  protein
identification.  The  non-redundant  NCBI  or  SwissProt
database  was  searched  using  MASCOT  1.9  through  the
Global Protein Server v3.5 from Applied Biosystems. All
determinations  were  performed  without  knowledge  of  the
corresponding clinical data (blind test).
Western blot: Tears collected from 10 patients (20 eyes) with
KC and 10 control subjects (20 eyes) were used to subsequent
validation of expression differences found using proteomics.
Ten μg of total protein extracted from the Schirmer strips were
loaded and size-separated in a 10% sodium dodecyl sulfate-
polyacrilamide gel electrophoresis (95 V). The proteins were
blotted  in  semi-dry  conditions  using  polyvinyl  difluoride
membranes (Millipore, Billerica, MA) and incubated with
primary  antibodies  raised  in  mouse  against  lactoferrin
(1:2,000; Abcam, Cambrigde, UK), immunoglobulin kappa
constant (IGKC) (1:2,000; Abcam) and zinc-α2-glycoprotein
(1:700; Santa Cruz Biotechnology, Santa Cruz, CA) overnight
at  4  °C.  For  detection,  a  goat  anti-mouse  Cy3-labeled
secondary antibody (1:3,000; GE) was used and images were
acquired  using  Molecular  Imager  FX  Pro-plus  (BioRad).
QuantityOne  software  (BioRad)  was  used  to  analyze  the
expression of the different bands of protein. To verify equal
protein loading, membranes were stripped at 50 °C for 30 min
in stripping buffer containing 62.5 mM Tris, 2% SDS and
100 mM β-ME, subsequently re-blocked and probed with
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)
antibody (1:3,000; Abcam). Experiments were performed in
duplicate.
Statistical  analysis:  Descriptive  statistical  analyses  were
performed  with  percentage  for  categorical  variables.
Discontinuous  variables  were  expressed  as  median
[quartiles]. Statistical significance for intergroup differences
was assessed by the χ2 test for categorical variables. One-way
ANOVA and the Mann–Whitney test were performed for
comparison  between  groups.  A  value  of  p<0.05  was
considered to be statistically significant. On the other hand,
protein patterns were analyzed using PDQuest 7.0 from Bio-
Rad.  The  reproducibility  of  the  gels  was  calculated  by
Pearson's coefficient. Differences were considered when spot
intensity  was  significantly  different  between  patients  and
controls (p<0.01) and at least two times greater in one group
respect to the other. The statistical analysis was conducted
Figure  1.  Master  gel  created  by
combining  spots  from  all  gels  of
keratoconus  patients  and  control
subjects.
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2057using  SPSS  16.0  (IBM,  Chicago  IL)  for  Windows  XP
(Microsoft Corporation, Redmond, WA).
RESULTS
Clinical Features: All of the KC eyes showed either moderate
or severe stage of progression: 18 eyes (40.9%) presented
moderate KC (K2 between 45 D and 52 D), 26 eyes (59.1%)
had severe KC (K2 >52 D).
Mean K2 was 54.8±7.1 D in the KC eyes, versus 43.7±1.6
D in the control subjects (p<0.0001). Mean of the thinnest
point pachymetry was 386.2±71.6 µm in the KC eyes, versus
542±23.9 µm in the control subjects eyes (p<0.0001).
Proteomic analysis: An average of 532 spots was observed in
both  groups  (Figure  1).  Gels  were  highly  reproducible
(r2=0.95) between groups. No qualitative differences have
been found, however three spots were found to be expressed
at least twofold in healthy subjects than in KC patients and
one spot was found twofold in KC patients than in healthy
subjects (Figure 2). The expression levels are shown in Table
2. Furthermore these differences were statistically significant
(p<0.001).  Mass  spectrometry  analysis  revealed  that
quantitative differences more expressed in healthy subjects
were; IGKC (Immunoglobulin Kappa Chain) protein, zinc-
α2-glycoprotein  (ZAG;  Figure  3),  and  lactoferrin  and
quantitative difference more expressed in KC patients was
identified as ZAG.
Western blot: Western blot analysis for IGKC protein, ZAG,
and lactoferrin showed a statistically significant decrease in
protein  expression  (optic  mean  intensity)  in  KC  patients
compared to healthy controls (p<0.05; Figure 4).
Figure  2.  Two-dimensional  gel
fragments  showing  differential
expressed proteins between keratoconus
patients and control subjects. Three of
them were more expressed in control
subjects  and  they  were  identified  as
zinc-α2-glycoprotein  (ZAG),
lactoferrin, and IGKC (immunoglobulin
kappa chain). The other spot was more
expressed  in  KC  patients  and  it  was
identified as ZAG.
TABLE 2. PROTEIN EXPRESSION VALUES FOR THE DIFFERENTIALLY EXPRESSED PROTEINS BETWEEN PATIENTS WITH
KERATOCONUS AND CONTROL SUBJECTS. THE VALUES OF THE PROTEIN EXPRESSION ARE SHOWED AS MEAN SPOT INTENSITY (A.U.).
Variables Keratoconus (n=12) Control (n=12) p
IGKC* 113.7±99.6 370.3±96.2 <0.001
ZAG† 819.1±247.2 2939.7±1700.9 <0.001
ZAG 63.5±23.4 16.8±2.9 <0.001
Lactoferrin 6.4±4.0 23.1±18.5 <0.001
          *IGKC: immunoglobulin kappa chain. †ZAG: zinc-α2-glycoprotein.
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2058DISCUSSION
Despite extensive basic and clinical studies of keratoconus in
recent  years,  the  precise  mechanisms  underlying  this
pathology still remain largely unknown. In this study, we
performed  a  detailed  proteomic  analysis  of  both  eyes  in
patients with bilateral KC and control subjects. Our results
show  the  usefulness  of  proteomics  to  find  out  protein
differences between KC patients and healthy subjects in tear
samples. By comparing the global protein expression in tears,
we found three spots whose expression was greater in the
healthy subjects (IGKC protein, ZAG, and lactoferrin) and
one spot was found to be more expressed in KC patients
(ZAG). It is not strange to detect two or even more spots that
belong to the same protein in a 2-DE gel. This is an indication
that the protein has different posttranslational modifications.
In our case, we have found two different spots for ZAG, one
of them is threefold less expressed in KC patients respect to
the controls, while the second spot is fourfold more expressed
in patients than in control subjects. This is not a contradiction;
one posttranslational modification could be more expressed
in one group while the other could be just in the opposite way.
Proteomics  papers  have  described  differences  in
posttranslational  modifications  in  tears,  specially
homopolymers  formation,  protease  degradation  and
glycosilation. Since ZAG is a glycoprotein, we hypothesized
that posttranslational modification should be a glycosilation
[19]. Nevertheless, what it is important is that overall the
protein  is  more  expressed  in  controls  than  in  patients,  as
reflected in the western-blot results, where each band includes
all posttranslational modifications (spots in 2-DE gels) of a
protein. Therefore, we conclude that ZAG is under-expressed
in KC patients respect to healthy subjects.
Tear lactoferrin is an 82 kDa protein produced in the
acinar cells of the lacrimal gland. Lactoferrin is present in
normal tears of humans and was found to be invariant through
age and independent of sex. It has been reported reduced levels
in certain diseases such as Sjögren syndrome, idiopathic dry
eye, vernal conjunctivitis, contact lens induced giant papillary
conjunctivitis,  trachoma,  herpes  simplex  keratitis,  chronic
irritative conjunctivitis keratoconjunctivitis sicca, and clinical
dry eye with a marked keratopathy [20]. In tear film lactoferrin
is  thought  to  be  antimicrobial  and  antiinflammatory.  In
particular, it has been demonstrated that Lipopolysaccharide-
induced  production  of  IL-6,  TNF-α,  IL-1-β,  and  IL-8  is
inhibited by lactoferrin, in various human monocytic cell lines
[21-24]. Previous studies from our group have demonstrated
that the levels of proinflammatory cytokines (interleukin-6
[IL-6]  and  the  tumor  necrosis  factor  alpha  [TNF-α])  are
significantly increased in the tears of patients with KC [13].
Likewise, it has been postulated that reactive oxygen and
nitrogen species are raised in keratocunus that, in turn, induce
collagenases  and  gelatinases  responsible  for  the  corneal
thinning process in this disease [13,25]. Consequently, it is
tempting to postulate that lactoferrin might be protective in
keratoconus because of its role in decreasing the expression
of proinflammatory cytokines and collagenases.
ZAG is a 41-kDa protein component of plasma, saliva,
and tears. It stimulates lipid breakdown in adipocytes and is
associated to the extreme weight loss that occurs in some
cancers [26]. On the other hand, structural organization and
fold is similar to MHC class I antigen-presenting molecule;
hence, ZAG may have a role in the expression of the immune
response [27]. We have demonstrated that the tears of patients
with  keratoconus  contain  a  smaller  amount  of  ZAG.
Contradictory  results  were  found  in  patients  with  Graves
ophthalmopathy where the expression of ZAG is increased
[28]. However, the specific role of ZAG in tears is not known.
Finally,  we  found  a  significant  decrease  in  protein
expression  for  IGKC  in  KC  patients.  IGKC  and
immunoglobulin kappa light chain variable region constitutes
the light chains of an antibody and is related with immune
response.  In  recent  years,  several  clinical  studies  of  KC
Figure 3. A typical profile of molecular
mass of tryptic fragments of zinc- α2-
glycoprotein (ZAG) during analysis by
MALDI-TOF mass spectrometry.
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2059support the idea that its pathogenesis involves an immune and
inflammatory component [29,30]. Indeed, previous studies
from our group, together with others, have shown that the
levels  of  proinflammatory  cytokines  are  significantly
increased in the tears of patients with KC [10,13,31].
The limited sample size of the present study weakens the
strength with which we may draw our conclusions. However,
the robustness of the results gives support to the need to
explore  the  role  of  these  molecular  markers  as  a  new
therapeutic or diagnostic tool in the KC. Although sample size
is not so large, similar proteomic studies have used similar
sample sizes [32]. Another limitation is that proteomics based
on  two-dimensional  gels  has  a  sensitivity  in  the  order  of
magnitude  of  nanograms.  Therefore,  proteins  whose
expression is below the nanogram scale cannot be detected on
the gels. Consequently, we do not rule out the possibility that
other differences (not identified because of the sensitivity of
staining methods) could exist between these two groups.
In conclusion, this study reveals that IGKC protein, zinc-
α2-glycoprotein, and lactoferrin are under-expressed in the
tears of patients diagnosed with bilateral KC compared with
healthy subjects. However, the precise role of each of these
molecular factors still needs to be defined, but the results
suggest that the pathogenesis of KC might involve immune
and inflammatory processes.
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